Abstract Objective To study the association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder (ADHD). Methods A total of 80 previously untreated children with ADHD who were diagnosed from May 2017 to October 2018 were enrolled. The children who were willing to receive drug therapy were randomly divided into concerta-treated group with 31 children and strattera-treated group with 33 children. The children who were unwilling to receive treatment were enrolled as the untreated group with 16 children. A total of 60 children who underwent physical examination during the same period of time were enrolled as the healthy control group. SNAP-V score was determined at initial diagnosis and 3 and 6 months of follow-up. Serum samples were collected from the children with ADHD and the healthy control group. Quantitative real-time PCR was used to measure the relative expression of miR-4566-3p and miR-7641. Results The repeated measures analysis of variance showed that the SNAP-V score of attention deficit symptoms were different among the two treatment groups and the untreated group at the first visit and 3 months and 6 months after treatment (P P P P P P > 0.05), and there was no interaction between the time factor and the grouping factor (P > 0.05). The SNAP-V score of attention deficit symptoms was negatively correlated with the relative expression of miRNA-4655-3p and miRNA-7641 (r=-0.314, -0.495 respectively; P Conclusions Drug therapy can significantly improve the clinical symptoms of children with ADHD. The expression of miR-4655-3p and miR-7641 in serum can be used as biomarkers for the diagnosis and outcome evaluation of ADHD.
ZHANG Fan,ZHU Ping,WU Li-Hui. Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder[J]. CJCP, 2020, 22(2): 152-157.
ZHANG Fan,ZHU Ping,WU Li-Hui. Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder[J]. CJCP, 2020, 22(2): 152-157.
Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades:an updated systematic review and meta-regression analysis[J]. Int J Epidemiol, 2014, 43(2):434-442.
[2]
Zhou F, Wu F, Zou S, et al. Dietary, nutrient patterns and blood essential elements in chinese children with ADHD[J]. Nutrients, 2016, 8(6). pii:E352.
[3]
Tandon PS, Sasser T, Gonzalez ES, et al. Physical activity, screen time, and sleep in children with ADHD[J]. J Phys Act Health, 2019, 16(6):416-422.
[4]
Song M, Lauseng D, Lee S, et al. Enhanced physical activity improves selected outcomes in children with ADHD:systematic review[J]. West J Nurs Res, 2016, 38(9):1155-1184.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay[J]. Nat Rev Genet, 2010, 11(9):597-610.
[7]
Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets[J]. Cell, 2003, 115(7):787-798.
[8]
Omran A, Elimam D, Shalaby S, et al. MicroRNAs:a light into the "black box" of neuropediatric diseases?[J]. Neuromolecular Med, 2012, 14(4):244-261.
[9]
Wright C, Gupta CN, Chen J, et al. Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia[J]. Transl Psychiatry, 2016, 6:e724.
[10]
Perkins DO, Jeffries CD, Jarskog LF, et al. MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder[J]. Genome Biol, 2007, 8(2):R27.
[11]
Wu LH, Peng M, Yu M, et al. Circulating microRNA let-7d in attention-deficit/hyperactivity disorder[J]. Neuromolecular Med, 2015, 17(2):137-146.
[12]
Wu L, Zhao Q, Zhu X, et al. A novel function of microRNA let-7d in regulation of galectin-3 expression in attention deficit hyperactivity disorder rat brain[J]. Brain Pathol, 2010, 20(6):1042-1054.
[13]
Wu LH, Cheng W, Yu M, et al. Nr3C1-Bhlhb2 axis dysregulation is involved in the development of attention deficit hyperactivity[J]. Mol Neurobiol, 2017, 54(2):1196-1212.
Piovesana AM, Harrison JL, Ducat JJ. The development of a motor-free short-form of the Wechsler Intelligence Scale for Children-Fifth Edition[J]. Assessment, 2019, 26(8):1564-1572.
[16]
Munkvold LH, Manger T, Lundervold AJ. Conners' continuous performance test (CCPT-II) in children with ADHD, ODD, or a combined ADHD/ODD diagnosis[J]. Child Neuropsychol, 2014, 20(1):106-126.
[17]
Austerman J. ADHD and behavioral disorders:assessment, management, and an update from DSM-5[J]. Cleve Clin J Med, 2015, 82(11 Suppl 1):S2-S7.
[18]
Sugrue D, Bogner R, Ehret MJ, et al. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder[J]. Am J Health Syst Pharm, 2014, 71(14):1163-1170.
[19]
Türkoğlu S, Çetin FH. Atomoxetine in the treatment of adolescent with trichotillomania and attention-deficit/hyperactivity disorder[J]. Clin Neuropharmacol, 2018, 41(2):84-85.
[20]
Hechtman L. ADHD medication treatment and risk of psychosis[J]. Lancet Psychiatry, 2019, 6(8):632-633.
Tabrez S, Jabir NR, Shakil S, et al. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease[J]. CNS Neurol Disord Drug Targets, 2012, 11(4):395-409.
[23]
Jiang Y, Liu J, Chen L, et al. Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson's disease[J]. Brain Res, 2019, 1722:146331.
